Details of the Drug Combinations

General Information of This Drug (ID: DM094UH)

• Drug Name: CB-839 (DM094UH)

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Phase 2 [1]; Renal cell carcinoma; ICD 11: 2C90; Status: Phase 2 [1]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 2 [1]; leukaemia; ICD 11: 2A60-2B33; Status: Phase 1 [2]

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
CB-839 + Talazoparib	DCAI3T3	Talazoparib	Solid Tumor	[3]
CB-839 + Famotidine	DCAKWHT	Famotidine	Drug Interaction	[4]
CB-839 + Capecitabine	DCBSGJK	Capecitabine	Colorectal Cancer	[5]
CB-839 + Cabozantinib	DCA8K1H	Cabozantinib	Advanced Renal Cell Carcinoma	[6]
CB-839 + Everolimus	DCUVHTP	Everolimus	Clear Cell Renal Cell Carcinoma	[7]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02071862) Study of the Glutaminase Inhibitor CB-839 in Solid Tumors. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT03875313) Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
• [4] ClinicalTrials.gov (NCT04540965) Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects
• [5] ClinicalTrials.gov (NCT02861300) CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
• [6] ClinicalTrials.gov (NCT03428217) CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
• [7] ClinicalTrials.gov (NCT03163667) CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)